DGX Quest Diagnostics Incorporated Common Stock
$240,04
Precio · Ago 19, 2026
Fundamentales a fecha de Jul 23, 2026
Rango 52S
$171–$242
97% of range
Calificación del Analista
HOLD
23 analysts
Precio Objetivo
$246
+2% upside
P/E (TTM)
27.7
ROE
14.2%
Margen de Beneficio Neto
9.0%
Acerca de Quest Diagnostics Incorporated Common Stock Descripción general de la empresa de Wikipedia
Quest Diagnostics Incorporated is an American clinical laboratory. A Fortune 500 company, Quest operates in the United States, Puerto Rico, Mexico, and Brazil. Quest also maintains collaborative agreements with various hospitals and clinics across the globe.
Leer más
Quest Diagnostics Incorporated is an American clinical laboratory. A Fortune 500 company, Quest operates in the United States, Puerto Rico, Mexico, and Brazil. Quest also maintains collaborative agreements with various hospitals and clinics across the globe.
As of 2020, the company had approximately 48,000 employees, and it generated more than $7.7 billion in revenue in 2019. The company offers access to diagnostic testing services for cancer, cardiovascular disease, infectious disease, neurological disorders, COVID-19, and employment and court-ordered drug testing.
History
1960–1995
Originally founded as Metropolitan Pathology Laboratory, Inc. in 1967 by Paul A. Brown, MD, the clinical laboratory underwent a variety of name changes. In 1969, the company's name changed to MetPath, Inc. with headquarters in Teaneck, New Jersey. By 1982, MetPath was acquired by what was then known as Corning Glass Works and was subsequently renamed Corning Clinical Laboratories.
1996–2000
On December 31, 1996, Quest Diagnostics became an independent company as a spin-off from Corning. Kenneth W. Freeman was appointed as CEO during this transition. Over the next year, Quest acquired a clinical laboratory division of Branford, Connecticut–based Diagnostic Medical Laboratory, Inc. (DML). Two years later in 1999, Quest added SmithKline Beecham Clinical Laboratories to their subsidiaries; which includes a joint venture ownership with CompuNet Clinical Laboratory. The purchase of SmithKline Beecham also included the lab's medical sample transport airline (ICAO: LBQ, call sign: LABQUEST) originally founded in 1988.
In 1997, Quest and Banner Health formed a joint venture creating the Arizona based Sonora Quest laboratory, a business unit of Laboratory Sciences of Arizona. This entity represents the operations of Quest Diagnostics in the Arizona regional market.
2001–2015
From May 2004 to April 2012, Surya Mohapatra served as the company's President and CEO. In 2007 Quest acquired diagnostic testing equipment company AmeriPath. In response to Mohapatra's resignation after eight years with Quest, former Philips Healthcare CEO Stephen Rusckowski was appointed. Under Rusckowski, Quest Diagnostics teamed up with central New England's largest health care system, UMass Memorial Health Care, to purchase its clinical outreach laboratory.
2016–present
In 2016, Quest collaborated with Safeway to bring testing services to twelve of its stores in California, Maryland, Virginia, Texas and Colorado.
By the end of 2017, Quest, in partnership with Walmart, incorporated laboratory testing in about 15 of their locations in Texas and Florida.
In May 2018, the company announced it will become an in-network laboratory provider to UnitedHealthcare starting in 2019, providing access to 48 million plan members.
In September 2018, Quest moved its headquarters from Madison, where it was located since 2007, to Secaucus, New Jersey.
In November 2018, Quest launched QuestDirect, a consumer-initiated testing service that allows patients to order health and wellness lab testing from home.
In March 2020, the company launched a COVID-19 testing service. As of July 2020, Quest had performed more than 9.2 million COVID-19 molecular tests and 2.8 million serology tests.
In April 2024, Quest has added a new blood screening to their AD-Detect product line. This test will analyze the blood for a specific Alzheimer's protein, pTau-217.
In February 2025, Quest acquired select assets of Fresenius Medical Care's Spectra laboratories. Under a separate agreement, Quest now offers clinical testing and lab services related to dialysis and end-stage kidney disease.
Acquisitions
Partnerships
2005: Forms a strategic alliance with Ciphergen Biosystems to commercialize novel proteomic tests.
Controversies
Quest Diagnostics set a record in April 2009 when it paid $302 million to the government to settle a Medicare fraud case alleging the company sold faulty medical testing kits. It was the largest qui tam (whistleblower) settlement paid by a medical laboratory for manufacturing and distributing a faulty product. In May 2011, Quest paid $241 million to the state of California to settle a False Claims Act case that alleged the company had overcharged Medi-Cal, the state's Medicaid program, and provided illegal kickbacks as incentives for healthcare providers to use Quest labs.
In 2018, Quest Diagnostics was among a number of U.S.–based laboratories linked to inaccuracies of over 200 women's cervical smear tests for CervicalCheck, Ireland's national screening program. Audits of the testing performed by Quest (and another subcontractor, Clinical Pathology Laboratories, Inc. of Austin, Texas) showed a high rate of errors in analysis of samples which led to lawsuits and a government inquiry. Quest and the Irish government continue to settle the resulting lawsuits.
On June 3, 2019, Quest announced that American Medical Collection Agency (AMCA), a billing collections service provider, had informed Quest Diagnostics that an unauthorized user had access to AMCA’s system containing personal information AMCA received from various entities, including from Quest. AMCA provides billing collections services to Optum360, which in turn is a Quest contractor. AMCA later went bankrupt after the breach.
Fuente: Wikipedia (Inglés), CC BY-SA 4.0 · Ver en Wikipedia ↗
DGX Instantánea de la Acción Precio, capitalización bursátil, P/E, BPA, ROE, deuda/capital, rango de 52 semanas
Precio
$240.04
Capitalización Bursátil
$26.64B
P/E (TTM)
27.7
BPA (TTM)
$8.75
Ingresos (TTM)
$11.04B
Rendimiento div.
1.3%
ROE
14.2%
Deuda/Capital
0.8
Rango 52S
$171 – $242
DGX Gráfico del Precio de la Acción OHLCV diario con indicadores técnicos — desplace, amplíe y personalice su vista
Configure
Rendimiento a 10 años Tendencias de ingresos, beneficio neto, márgenes y BPA
Ingresos y Beneficio Neto
$11.04B
2016-12-31
→
2025-12-31
BPA
$8.75
2016-12-31
→
2025-12-31
Flujo de caja libre
$1.36B
2016-12-31
→
2025-12-31
Márgenes
9.0%
2016-12-31
→
2020-12-31
Valoración Ratios P/E, P/S, P/B, EV/EBITDA: ¿está la acción cara o barata?
Métrica
Tendencia a 5 años
DGX
Mediana de Pares
P/E (TTM)
27.7
26.5
P/S (TTM) (P/V (TTM))
2.4
2.0
P/B (P/C)
3.7
4.9
EV / EBITDA
15.0
—
Price / FCF (Precio / FCF)
19.6
—
Rentabilidad Márgenes brutos, operativos y netos; ROE, ROA, ROIC
Métrica
Tendencia a 5 años
DGX
Mediana de Pares
Operating Margin (Margen Operativo)
14.1%
—
Net Profit Margin (Margen de Beneficio Neto)
9.0%
4.0%
ROA
6.1%
5.0%
ROE
14.2%
15.2%
ROIC
9.2%
—
Salud financiera Deuda, liquidez, solvencia — solidez del balance general
Métrica
Tendencia a 5 años
DGX
Mediana de Pares
Debt / Equity (Deuda / Patrimonio)
0.8
—
Current Ratio (Ratio corriente)
1.0
1.6
Quick Ratio (Ratio Rápido)
0.8
—
Crecimiento Crecimiento de ingresos, BPA y beneficio neto: interanual, CAGR a 3 años, CAGR a 5 años
Métrica
Tendencia a 5 años
DGX
Mediana de Pares
Revenue YoY (Ingresos interanuales)
11.8%
—
Revenue CAGR 3Y (Ingresos CAGR 3A)
3.7%
—
Revenue CAGR 5Y (Ingresos CAGR 5A)
3.2%
—
EPS YoY (EPS interanual)
13.8%
—
Net Income YoY (Beneficio Neto interanual)
13.9%
—
Eficiencia de capital Rotación de activos, rotación de inventario, rotación de cuentas por cobrar
Métrica
Tendencia a 5 años
DGX
Mediana de Pares
Payout Ratio (Ratio de Pago)
35.6%
—
Dividendos Rendimiento, ratio de pago, historial de dividendos, CAGR a 5 años
Rendimiento por Dividendo
1.3%
Ratio de Pago
35.6%
CAGR de Dividendos a 5 años
—
| Fecha ex-dividendo | Monto |
|---|---|
| 8 de julio de 2026 | $0,8600 |
| 6 de abril de 2026 | $0,8600 |
| 13 de enero de 2026 | $0,8000 |
| 3 de octubre de 2025 | $0,8000 |
| 7 de julio de 2025 | $0,8000 |
| 7 de abril de 2025 | $0,8000 |
| 14 de enero de 2025 | $0,7500 |
| 4 de octubre de 2024 | $0,7500 |
| 8 de julio de 2024 | $0,7500 |
| 5 de abril de 2024 | $0,7500 |
| 16 de enero de 2024 | $0,7100 |
| 5 de octubre de 2023 | $0,7100 |
| 10 de julio de 2023 | $0,7100 |
| 6 de abril de 2023 | $0,7100 |
| 17 de enero de 2023 | $0,6600 |
| 3 de octubre de 2022 | $0,6600 |
| 5 de julio de 2022 | $0,6600 |
| 5 de abril de 2022 | $0,6600 |
| 18 de enero de 2022 | $0,6200 |
| 4 de octubre de 2021 | $0,6200 |
DGX Consenso de analistas Opiniones de analistas alcistas y bajistas, precio objetivo a 12 meses, potencial alcista
COMPRA
23 analistas
- Compra fuerte 6 26,1%
- Compra 7 30,4%
- Mantener 10 43,5%
- Venta 0 0,0%
- Venta fuerte 0 0,0%
Precio objetivo a 12 meses
15 analistas · 2026-08-16
Mediana
$250.00
Ahora
$240.04
Mín
$204.00
Máx
$265.00
Objetivo mediano
$250.00
+4,1%
Objetivo medio
$245.87
+2,4%
Historial de Ganancias EPS real vs estimado, sorpresa %, tasa de aciertos, próxima fecha de resultados
Sorpresa Media
0.09%
| Período | EPS Actual | EPS est. | Sorpresa |
|---|---|---|---|
| 30 de junio de 2026 | $3.12 | $2.85 | 0.27% |
| 31 de marzo de 2026 | $2.50 | $2.37 | 0.13% |
| 31 de diciembre de 2025 | $2.42 | $2.38 | 0.04% |
| 30 de septiembre de 2025 | $2.60 | $2.53 | 0.07% |
| 30 de junio de 2025 | $2.62 | $2.60 | 0.02% |
| 31 de marzo de 2025 | $2.21 | $2.17 | 0.04% |
Comparación de pares (subindustria GICS) Métricas clave frente a competidores del sector
| Ticker | Capitalización Bursátil | P/E | Ingresos interanuales | Margen Neto | ROE | Margen Bruto |
|---|---|---|---|---|---|---|
| DGX | $19.09B | 19.8 | 11.8% | 9.0% | 14.2% | — |
| CVS | $100.87B | 57.1 | 7.8% | 0.44% | 2.4% | — |
| CI | $72.51B | 12.4 | 11.2% | 2.2% | 14.4% | — |
| LH | $20.62B | 24.0 | 7.2% | 6.3% | 10.3% | 28.8% |
| GH | $13.34B | -30.8 | 32.9% | -42.4% | 205.7% | — |
| LH | $20.62B | 24.0 | 7.2% | 6.3% | 10.3% | 28.8% |
| BTSG | $7.20B | 43.0 | 28.2% | 1.5% | 10.8% | 11.8% |
| DVA | $7.79B | 11.5 | 6.5% | 5.5% | -281.8% | — |
| HNGE | $0 | -6.0 | 50.6% | -89.9% | -299.8% | 79.7% |
| CHE | — | 23.3 | 4.1% | 10.5% | 24.4% | — |
| HIMS | — | 63.7 | 59.0% | 5.5% | 23.3% | 73.8% |
Fundamentales Completos Todas las métricas por año — estado de resultados, balance general, flujo de caja
Estado de resultados 17
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $11.04B | $9.87B | $9.25B | $9.88B | $10.79B | $9.44B | $7.73B | $7.53B | $7.40B | $7.21B | $7.49B | $7.43B | |
| Cost of Revenue | $7.37B | $6.63B | $6.20B | $6.45B | $6.58B | $5.80B | $5.04B | $4.93B | $4.72B | $4.62B | $4.66B | $4.64B | |
| Gross Profit | · | · | · | · | · | $3.63B | $2.69B | $2.60B | $2.68B | $2.90B | $2.84B | $2.80B | |
| SG&A Expense | $1.97B | $1.77B | $1.64B | $1.87B | $1.73B | $1.55B | $1.46B | $1.42B | $1.44B | $1.38B | $1.68B | $1.73B | |
| Operating Expenses | $9.48B | $8.53B | $7.99B | $8.46B | $8.41B | $7.47B | $6.50B | $6.43B | $6.24B | $5.94B | $6.09B | $6.45B | |
| Operating Income | $1.56B | $1.35B | $1.26B | $1.43B | $2.38B | $1.97B | $1.23B | $1.10B | $1.17B | $1.28B | $1.40B | $983M | |
| Interest Expense | · | · | $163M | $148M | $152M | $166M | $180M | $169M | $153M | $144M | $154M | $167M | |
| Interest Income | $13M | $25M | $11M | $10M | $1M | $3M | $5M | $2M | $2M | $1M | $1M | $3M | |
| Other Non-op | $26M | $30M | $20M | $-55M | $369M | $76M | $20M | $-8M | $16M | $-48M | $-143M | $4M | |
| Pretax Income | $1.32B | $1.18B | $1.13B | $1.24B | $2.60B | $1.88B | $1.08B | $926M | $1.03B | $1.09B | $1.10B | $823M | |
| Income Tax | $314M | $273M | $248M | $264M | $597M | $460M | $247M | $182M | $241M | $429M | $373M | $262M | |
| Net Income | $992M | $871M | $854M | $946M | $2.00B | $1.43B | $858M | $736M | $772M | $645M | $709M | $556M | |
| EPS (Basic) | $8.87 | $7.78 | $7.59 | $8.10 | $15.85 | $10.62 | $6.36 | $5.39 | $5.63 | $4.58 | $4.92 | $3.83 | |
| EPS (Diluted) | $8.75 | $7.69 | $7.49 | $7.97 | $15.55 | $10.47 | $6.28 | $5.29 | $5.50 | $4.51 | $4.87 | $3.81 | |
| Shares (Basic) | 111,000,000 | 111,000,000 | 112,000,000 | 116,000,000 | 125,000,000 | 134,000,000 | 134,000,000 | 136,000,000 | 137,000,000 | 140,000,000 | 144,000,000 | 145,000,000 | |
| Shares (Diluted) | 113,000,000 | 113,000,000 | 113,000,000 | 118,000,000 | 128,000,000 | 136,000,000 | 136,000,000 | 139,000,000 | 140,000,000 | 142,000,000 | 145,000,000 | 145,000,000 | |
| EBITDA | $2.13B | $1.84B | $1.70B | $1.86B | $2.79B | $2.33B | $1.56B | $1.41B | $1.44B | $1.53B | $1.70B | $1.30B |
Balance general 27
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $420M | $549M | $686M | $315M | $872M | $1.16B | $1.19B | $135M | $137M | $359M | $133M | $192M | |
| Receivables | $1.41B | $1.30B | $1.21B | $1.20B | $1.44B | $1.52B | $1.06B | $1.01B | $924M | $926M | $901M | $932M | |
| Inventory | $189M | $188M | $190M | $192M | $208M | $223M | $123M | $99M | $95M | $82M | $84M | $110M | |
| Prepaid Expense | $361M | $351M | $286M | $196M | $223M | $157M | $112M | $144M | $150M | $155M | $207M | $186M | |
| Current Assets | $2.38B | $2.39B | $2.37B | $1.90B | $2.74B | $3.06B | $2.49B | $1.39B | $1.31B | $1.53B | $1.50B | $1.60B | |
| PP&E (Net) | $2.20B | $2.11B | $1.82B | $1.77B | $1.71B | $1.63B | $1.45B | $1.29B | $1.15B | $1.03B | $925M | $933M | |
| PP&E (Gross) | $6.18B | $5.77B | $5.23B | $5.10B | $4.79B | $4.62B | $4.23B | $3.97B | $3.67B | $3.43B | $3.23B | $3.13B | |
| Accum. Depreciation | $3.97B | $3.66B | $3.42B | $3.34B | $3.09B | $2.99B | $2.78B | $2.68B | $2.53B | $2.40B | $2.31B | $2.19B | |
| Goodwill | $8.95B | $8.86B | $7.73B | $7.22B | $7.09B | $6.87B | $6.62B | $6.56B | $6.33B | $6.00B | $5.91B | $6.03B | |
| Intangibles | $1.64B | $1.76B | $1.17B | $1.09B | $1.17B | $1.17B | $1.12B | $1.21B | $1.12B | $949M | $984M | $1.07B | |
| Other Non-current Assets | $270M | $255M | $198M | $144M | $163M | $176M | $160M | $119M | $136M | $148M | $174M | $172M | |
| Total Assets | $16.23B | $16.15B | $14.02B | $12.84B | $13.61B | $14.03B | $12.84B | $11.00B | $10.50B | $10.10B | $9.96B | $9.86B | |
| Accounts Payable | $1.60B | $1.39B | $1.36B | $1.40B | $1.60B | $1.63B | $1.04B | $1.02B | $1.02B | $975M | $1.01B | $1.19B | |
| Accrued Liabilities | $338M | $306M | $287M | $392M | $460M | $356M | $223M | $274M | $246M | $254M | $257M | $277M | |
| Current Liabilities | $2.28B | $2.17B | $1.81B | $1.55B | $1.75B | $1.78B | $1.99B | $1.49B | $1.06B | $981M | $1.17B | $1.71B | |
| Capital Leases | $537M | $535M | $503M | $489M | $494M | $499M | $413M | $0 | · | · | · | · | |
| Deferred Tax | · | · | · | · | · | · | $264M | $243M | $170M | $191M | $157M | $204M | |
| Other Non-current Liabilities | $957M | $938M | $876M | $812M | $792M | $847M | $711M | $745M | $663M | $654M | $514M | $594M | |
| Long-term Debt | $5.67B | $6.22B | $4.71B | $3.98B | $4.01B | $4.01B | $4.77B | $3.89B | $3.78B | $3.73B | $3.65B | $3.74B | |
| Total Debt | $5.67B | $6.22B | $4.71B | $3.98B | $4.01B | $4.01B | $4.77B | $3.89B | $3.78B | $3.73B | $3.65B | $3.76B | |
| Common Stock | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | |
| Retained Earnings | $9.99B | $9.36B | $8.82B | $8.29B | $7.65B | $9.30B | $8.17B | $7.60B | $7.14B | $6.61B | $6.20B | $5.72B | |
| Treasury Stock | $5.18B | $4.86B | $4.83B | $4.67B | $3.45B | $5.37B | $5.22B | $5.00B | $4.78B | $4.46B | $3.96B | $3.81B | |
| AOCI | $-27M | $-88M | $-14M | $-21M | $-14M | $-21M | $-39M | $-59M | $-48M | $-72M | $-38M | $-27M | |
| Stockholders' Equity | $7.17B | $6.78B | $6.31B | $5.89B | $6.44B | $6.76B | $5.64B | $5.22B | $4.92B | $4.63B | $4.68B | $4.30B | |
| Liabilities + Equity | $16.23B | $16.15B | $14.02B | $12.84B | $13.61B | $14.03B | $12.84B | $11.00B | $10.50B | $10.10B | $9.96B | $9.86B | |
| Shares Outstanding | 110,000,000 | 111,000,000 | 111,000,000 | 111,000,000 | 119,000,000 | 133,000,000 | 133,000,000 | 135,000,000 | 135,000,000 | 137,000,000 | 143,000,000 | 144,000,000 |
Flujo de Efectivo 17
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $570M | $493M | $439M | $437M | $408M | $361M | $329M | $309M | $270M | $249M | $304M | $314M | |
| Stock-based Comp | $88M | $88M | $77M | $77M | $79M | $97M | $56M | $61M | $79M | $69M | $52M | $51M | |
| Deferred Tax | $105M | $13M | $-49M | $1M | $-57M | $85M | $15M | $73M | $9M | $37M | $112M | $23M | |
| Amort. of Intangibles | $154M | $127M | $108M | $120M | $103M | $103M | $96M | $90M | $74M | $72M | $81M | $94M | |
| Restructuring | · | · | · | $55M | $13M | $14M | $-3M | $49M | $30M | $11M | $39M | $43M | |
| Other Non-cash | $131M | $-131M | $-49M | $257M | $-192M | $31M | $-15M | $21M | $45M | $69M | $-367M | $-6M | |
| Operating Cash Flow | $1.89B | $1.33B | $1.27B | $1.72B | $2.23B | $2.00B | $1.24B | $1.20B | $1.18B | $1.12B | $821M | $944M | |
| CapEx | $527M | $425M | $408M | $404M | $403M | $418M | $400M | $383M | $252M | $293M | $263M | $308M | |
| Investing Cash Flow | $-631M | $-2.55B | $-1.06B | $-543M | $21M | $-772M | $-411M | $-801M | $-830M | $-127M | $-362M | $-1.02B | |
| Stock Repurchased | $450M | $151M | $275M | $1.41B | $2.20B | $325M | $353M | $322M | $465M | $590M | $224M | $132M | |
| Net Stock Activity | $-450M | $-151M | $-275M | $-1.41B | $-2.20B | $-325M | $-353M | $-322M | $-465M | $-590M | $-224M | $-132M | |
| Dividends Paid | $353M | $331M | $314M | $305M | $309M | $297M | $286M | $266M | $247M | $223M | $212M | $187M | |
| Financing Cash Flow | $-1.39B | $1.08B | $160M | $-1.73B | $-2.54B | $-1.27B | $225M | $-401M | $-592M | $-738M | $-518M | $86M | |
| Net Change in Cash | $-129M | $-137M | $371M | $-557M | $-286M | · | · | · | $-222M | $226M | $-59M | $5M | |
| Taxes Paid | $169M | $256M | $317M | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $1.36B | $909M | $864M | $1.31B | $1.83B | $1.59B | $843M | $817M | $923M | $776M | $547M | $630M | |
| Levered FCF | · | · | $737M | $1.20B | $1.71B | $1.46B | $704M | $681M | $806M | $689M | · | · |
Rentabilidad 8
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | · | · | · | · | · | 38.5% | 34.8% | 34.6% | 38.8% | 38.6% | 37.9% | 37.6% | |
| Operating Margin | 14.1% | 13.6% | 13.6% | 14.4% | 22.1% | 20.9% | 15.9% | 14.6% | 15.1% | 17.0% | 18.7% | 13.2% | |
| Net Margin | 9.0% | 8.8% | 9.2% | 9.6% | 18.5% | 15.2% | 11.1% | 9.8% | 10.0% | 8.6% | 9.5% | 7.5% | |
| Pretax Margin | 11.9% | 11.9% | 12.2% | 12.5% | 24.1% | 20.0% | 13.9% | 12.3% | 13.4% | 14.4% | 14.7% | · | |
| EBITDA Margin | 19.3% | 18.6% | 18.4% | 18.9% | 25.9% | 24.7% | 20.2% | 18.7% | 18.6% | 20.3% | 22.7% | 17.4% | |
| ROA | 6.1% | 5.8% | 6.4% | 7.1% | 14.4% | 10.7% | 7.2% | 6.8% | 7.5% | 6.4% | 7.1% | 5.9% | |
| ROE | 14.2% | 13.3% | 14.0% | 15.3% | 30.2% | 23.1% | 15.8% | 14.5% | 16.2% | 13.9% | 15.8% | 13.5% | |
| ROIC | 9.2% | 8.0% | 8.9% | 11.4% | 17.5% | 13.8% | 9.1% | 9.7% | 10.2% | 9.2% | 11.1% | · |
Liquidez y Solvencia 5
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.0 | 1.1 | 1.3 | 1.2 | 1.6 | 1.7 | 1.3 | 0.9 | 1.2 | 1.6 | 1.3 | 0.9 | |
| Quick Ratio | 0.8 | 0.9 | 1.0 | 1.0 | 1.3 | 1.5 | 1.1 | 0.8 | 1.0 | 1.3 | 0.9 | 0.7 | |
| Debt / Equity | 0.8 | 0.9 | 0.7 | 0.7 | 0.6 | 0.6 | 0.8 | 0.7 | 0.8 | 0.8 | 0.8 | 0.9 | |
| LT Debt / Equity | 0.7 | 0.8 | 0.7 | 0.7 | 0.6 | 0.6 | 0.7 | 0.7 | 0.8 | 0.8 | 0.7 | 0.8 | |
| Interest Coverage | · | · | 7.7 | 9.6 | 15.7 | 11.9 | 6.8 | 6.5 | 7.6 | 8.9 | · | · |
Eficiencia 3
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.7 | 0.7 | 0.7 | 0.7 | 0.8 | 0.7 | 0.6 | 0.7 | 0.7 | 0.7 | 0.8 | 0.8 | |
| Inventory Turnover | 39.1 | 35.1 | 32.5 | 32.2 | 30.5 | 33.5 | 45.4 | 50.8 | 53.3 | 55.6 | 48.0 | 46.1 | |
| Receivables Turnover | 8.1 | 7.9 | 7.7 | 7.5 | 7.3 | 7.3 | 7.4 | 7.8 | 8.3 | 8.2 | 8.2 | 8.3 |
Tasas de Crecimiento 10
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 11.8% | 6.7% | -6.4% | -8.4% | 14.3% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 3.7% | -2.9% | -0.66% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 3.2% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | 13.8% | 2.7% | -6.0% | -48.8% | 48.5% | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | 3.2% | -20.9% | -10.6% | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | -3.5% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | 13.9% | 2.0% | -9.7% | -52.6% | 39.4% | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | 1.6% | -24.1% | -15.8% | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 5Y | -7.1% | · | · | · | · | · | · | · | · | · | · | · | |
| Dividend CAGR 5Y | 3.5% | · | · | · | · | · | · | · | · | · | · | · |
Valoración (TTM) 16
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $11.04B | $9.87B | $9.25B | $9.88B | $10.79B | $9.44B | $7.73B | $7.53B | $7.40B | $7.21B | $7.49B | $7.43B | |
| Net Income TTM | $992M | $871M | $854M | $946M | $2.00B | $1.43B | $858M | $736M | $772M | $645M | $709M | $556M | |
| Market Cap | $19.09B | $16.75B | $15.30B | $17.36B | $20.59B | $15.85B | $14.20B | $11.24B | $13.30B | $12.59B | $10.17B | $9.66B | |
| Enterprise Value | $24.34B | $22.41B | $19.33B | $21.03B | $23.73B | $18.71B | $17.78B | $15.00B | $16.94B | $15.97B | $13.69B | $13.23B | |
| P/E | 19.8 | 19.6 | 18.4 | 19.6 | 11.1 | 11.4 | 17.0 | 15.7 | 17.9 | 20.4 | 14.6 | 17.6 | |
| P/S | 1.7 | 1.7 | 1.7 | 1.8 | 1.9 | 1.7 | 1.8 | 1.5 | 1.8 | 1.7 | 1.4 | 1.3 | |
| P/B | 2.7 | 2.5 | 2.4 | 2.9 | 3.2 | 2.3 | 2.5 | 2.2 | 2.7 | 2.7 | 2.2 | 2.2 | |
| P / Cash Flow | 10.1 | 12.6 | 12.0 | 10.1 | 9.2 | 7.9 | 11.4 | 9.4 | 11.3 | 11.8 | 12.6 | 10.3 | |
| P / FCF | 14.0 | 18.4 | 17.7 | 13.2 | 11.3 | 10.0 | 16.8 | 13.8 | 14.4 | 16.2 | 18.6 | 15.3 | |
| EV / EBITDA | 11.4 | 12.2 | 11.4 | 11.3 | 8.5 | 8.0 | 11.4 | 10.6 | 11.8 | 10.5 | 8.0 | 10.2 | |
| EV / FCF | 17.9 | 24.7 | 22.4 | 16.0 | 13.0 | 11.8 | 21.1 | 18.4 | 18.4 | 20.6 | 25.0 | 21.0 | |
| EV / Revenue | 2.2 | 2.3 | 2.1 | 2.1 | 2.2 | 2.0 | 2.3 | 2.0 | 2.3 | 2.2 | 1.8 | 1.8 | |
| Dividend Yield | 1.8% | 2.0% | 2.1% | 1.8% | 1.5% | 1.9% | 2.0% | 2.4% | 1.9% | 1.8% | 2.1% | 1.9% | |
| Earnings Yield | 5.0% | 5.1% | 5.4% | 5.1% | 9.0% | 8.8% | 5.9% | 6.3% | 5.6% | 4.9% | 6.9% | 5.7% | |
| Payout Ratio | 35.6% | 38.0% | 36.8% | 32.2% | 15.5% | 20.8% | 33.3% | 36.1% | 32.0% | 34.6% | 29.9% | 33.6% | |
| Annual Payout | $353M | $331M | $314M | $305M | $309M | $297M | $286M | $266M | $247M | $223M | $212M | $187M |
Estado de resultados 16
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.04B | $2.90B | $2.81B | $2.82B | $2.76B | $2.65B | $2.62B | $2.49B | $2.40B | $2.37B | $2.29B | $2.29B | $2.34B | $2.33B | $2.33B | $2.49B | |
| Cost of Revenue | $2.02B | $1.95B | $1.90B | $1.87B | $1.82B | $1.79B | $1.76B | $1.68B | $1.59B | $1.59B | $1.55B | $1.54B | $1.55B | $1.56B | $1.57B | $1.62B | |
| SG&A Expense | $529M | $504M | $504M | $501M | $486M | $476M | $466M | $448M | $416M | $440M | $407M | $380M | $416M | $439M | $563M | $464M | |
| Operating Expenses | $2.58B | $2.50B | $2.42B | $2.43B | $2.32B | $2.31B | $2.26B | $2.16B | $2.04B | $2.07B | $2.02B | $1.95B | $1.99B | $2.03B | $2.20B | $2.09B | |
| Operating Income | $459M | $399M | $386M | $386M | $438M | $346M | $361M | $330M | $355M | $300M | $267M | $342M | $348M | $305M | $135M | $392M | |
| Interest Expense | · | · | · | · | · | · | · | · | $47M | $49M | · | $41M | $39M | $37M | · | $37M | |
| Interest Income | $5M | $2M | $3M | $3M | $2M | $5M | $7M | $9M | $3M | $6M | $6M | $1M | $2M | $2M | $4M | $4M | |
| Other Non-op | $16M | $-2M | $8M | $8M | $13M | $-3M | $3M | $15M | $3M | $9M | $10M | $-3M | $6M | $7M | $6M | $-8M | |
| Pretax Income | $412M | $334M | $330M | $328M | $384M | $276M | $299M | $296M | $314M | $266M | $237M | $299M | $317M | $277M | $109M | $351M | |
| Income Tax | $88M | $74M | $81M | $77M | $97M | $59M | $68M | $65M | $74M | $66M | $40M | $68M | $75M | $65M | $-4M | $81M | |
| Net Income | $320M | $252M | $245M | $245M | $282M | $220M | $222M | $226M | $229M | $194M | $192M | $225M | $235M | $202M | $101M | $256M | |
| EPS (Basic) | $2.88 | $2.27 | $2.21 | $2.18 | $2.51 | $1.97 | $1.98 | $2.01 | $2.05 | $1.74 | $1.72 | $1.99 | $2.08 | $1.80 | $0.93 | $2.20 | |
| EPS (Diluted) | $2.84 | $2.24 | $2.18 | $2.16 | $2.47 | $1.94 | $1.95 | $1.99 | $2.03 | $1.72 | $1.70 | $1.96 | $2.05 | $1.78 | $0.92 | $2.17 | |
| Shares (Basic) | 111,000,000 | 110,000,000 | -224,000,000 | 112,000,000 | 112,000,000 | 111,000,000 | -223,000,000 | 112,000,000 | 111,000,000 | 111,000,000 | -224,000,000 | 112,000,000 | 112,000,000 | 112,000,000 | -236,000,000 | 116,000,000 | |
| Shares (Diluted) | 112,000,000 | 112,000,000 | -226,000,000 | 113,000,000 | 113,000,000 | 113,000,000 | -224,000,000 | 113,000,000 | 112,000,000 | 112,000,000 | -228,000,000 | 114,000,000 | 114,000,000 | 113,000,000 | -240,000,000 | 118,000,000 | |
| EBITDA | $605M | $546M | · | $528M | $581M | $486M | · | $455M | $472M | $416M | · | $453M | $460M | $412M | · | $500M |
Balance general 26
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $626M | $393M | $420M | $432M | $319M | $188M | $549M | $764M | $271M | $474M | · | $143M | $126M | $175M | · | $700M | |
| Receivables | $1.67B | $1.59B | $1.41B | $1.46B | $1.42B | $1.40B | $1.30B | $1.38B | $1.32B | $1.32B | · | $1.28B | $1.24B | $1.25B | · | $1.28B | |
| Inventory | $233M | $225M | $189M | $186M | $187M | $189M | $188M | $184M | $182M | $181M | · | $184M | $184M | $190M | · | $183M | |
| Prepaid Expense | $319M | $361M | $361M | $333M | $273M | $294M | $351M | $299M | $245M | $251M | · | $207M | $188M | $195M | · | $171M | |
| Current Assets | $2.84B | $2.57B | $2.38B | $2.41B | $2.20B | $2.08B | $2.39B | $2.62B | $2.02B | $2.23B | · | $1.81B | $1.73B | $1.81B | · | $2.33B | |
| PP&E (Net) | $2.22B | $2.19B | $2.20B | $2.15B | $2.12B | $2.10B | $2.11B | $2.09B | $1.83B | $1.81B | · | $1.83B | $1.81B | $1.79B | · | $1.71B | |
| PP&E (Gross) | · | · | $6.18B | · | · | · | $5.77B | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $3.97B | · | · | · | $3.66B | · | · | · | · | · | · | · | · | · | |
| Goodwill | $9.11B | $9.12B | $8.95B | $8.90B | $8.88B | $8.85B | $8.86B | $8.61B | $7.88B | $7.83B | $7.73B | $7.73B | $7.73B | $7.24B | $7.22B | $7.19B | |
| Intangibles | $1.67B | $1.72B | $1.64B | $1.66B | $1.71B | $1.73B | $1.76B | $1.72B | $1.20B | $1.19B | · | $1.22B | $1.25B | $1.08B | · | $1.11B | |
| Other Non-current Assets | $277M | $256M | $270M | $296M | $271M | $260M | $255M | $272M | $216M | $182M | · | $149M | $152M | $150M | · | $132M | |
| Total Assets | $16.94B | $16.67B | $16.23B | $16.20B | $15.97B | $15.80B | $16.15B | $16.09B | $13.88B | $13.95B | · | $13.48B | $13.43B | $12.79B | · | $13.22B | |
| Accounts Payable | $1.60B | $1.50B | $1.60B | $1.46B | $1.35B | $1.27B | $1.39B | $1.31B | $1.25B | $1.24B | · | $1.16B | $1.20B | $1.20B | · | $1.45B | |
| Accrued Liabilities | · | · | $338M | · | · | · | $306M | · | · | · | · | · | · | · | · | · | |
| Current Liabilities | $1.79B | $2.18B | $2.28B | $2.13B | $2.02B | $1.44B | $2.17B | $2.09B | $2.01B | $2.30B | · | $1.62B | $1.88B | $1.35B | · | $1.60B | |
| Capital Leases | $561M | $574M | $537M | $534M | $540M | $538M | $535M | $543M | $507M | $489M | · | $505M | $508M | $490M | · | $505M | |
| Other Non-current Liabilities | $1.06B | $1.02B | $957M | $982M | $890M | $917M | $938M | $891M | $811M | $817M | · | $874M | $901M | $809M | · | $787M | |
| Long-term Debt | $5.64B | · | $5.67B | · | · | · | $6.22B | $6.25B | · | · | · | · | · | · | · | · | |
| Total Debt | $5.64B | $503M | · | $504M | $504M | $1M | · | $6.25B | $606M | $906M | · | $304M | $518M | $2M | · | $2M | |
| Common Stock | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | · | $2M | $2M | $2M | · | $2M | |
| Retained Earnings | $10.37B | $10.15B | $9.99B | $9.84B | $9.68B | $9.49B | $9.36B | $9.22B | $9.08B | $8.94B | · | $8.71B | $8.57B | $8.41B | · | $8.26B | |
| Treasury Stock | $5.17B | $5.09B | $5.18B | $4.90B | $4.77B | $4.79B | $4.86B | $4.73B | $4.76B | $4.78B | · | $4.57B | $4.59B | $4.61B | · | $4.27B | |
| AOCI | $-62M | $-43M | $-27M | $-40M | $-16M | $-83M | $-88M | $-15M | $-19M | $-16M | · | $-20M | $-16M | $-18M | · | $-31M | |
| Stockholders' Equity | $7.52B | $7.37B | $7.17B | $7.26B | $7.23B | $6.93B | $6.78B | $6.81B | $6.62B | $6.43B | · | $6.42B | $6.25B | $6.05B | · | $6.24B | |
| Liabilities + Equity | $16.94B | $16.67B | $16.23B | $16.20B | $15.97B | $15.80B | $16.15B | $16.09B | $13.88B | $13.95B | · | $13.48B | $13.43B | $12.79B | · | $13.22B | |
| Shares Outstanding | 110,000,000 | 111,000,000 | 110,000,000 | 111,000,000 | 112,000,000 | 112,000,000 | 111,000,000 | 112,000,000 | 111,000,000 | 111,000,000 | 111,000,000 | 112,000,000 | 112,000,000 | 112,000,000 | 111,000,000 | 114,000,000 |
Flujo de Efectivo 16
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $146M | $147M | $145M | $142M | $143M | $140M | $135M | $125M | $117M | $116M | $109M | $111M | $112M | $107M | $116M | $108M | |
| Stock-based Comp | $23M | $20M | $25M | $20M | $21M | $22M | $27M | $19M | $20M | $22M | $19M | $18M | $16M | $24M | $22M | $18M | |
| Deferred Tax | $-2M | $48M | $-13M | $110M | $1M | $7M | $34M | $15M | $-18M | $-18M | $-10M | $-23M | $-12M | $-4M | $-44M | $65M | |
| Amort. of Intangibles | $38M | $37M | $37M | $39M | $39M | $39M | $37M | $32M | $29M | $29M | $27M | $27M | $28M | $26M | $39M | $27M | |
| Restructuring | · | · | · | $6M | $1M | · | · | $7M | $8M | · | · | $1M | $1M | · | · | · | |
| Other Non-cash | · | $-189M | · | · | · | $-75M | · | · | · | $-160M | · | · | · | $-235M | · | · | |
| Operating Cash Flow | $597M | $278M | $465M | $563M | $544M | $314M | $464M | $356M | $360M | $154M | $527M | $207M | $444M | $94M | $334M | $502M | |
| CapEx | $138M | $114M | $158M | $144M | $108M | $117M | $123M | $106M | $92M | $104M | $72M | $105M | $104M | $127M | $147M | $118M | |
| Investing Cash Flow | $-134M | $-152M | $-191M | $-201M | $-124M | $-115M | $-502M | $-1.63B | $-200M | $-213M | $-114M | $-107M | $-682M | $-158M | $-174M | $-118M | |
| Stock Repurchased | · | · | $300M | $150M | · | · | $151M | · | · | · | $275M | $0 | $0 | $0 | $461M | $374M | |
| Net Stock Activity | · | · | · | · | · | · | · | · | · | · | · | · | · | $0 | · | · | |
| Dividends Paid | $96M | $88M | $90M | $89M | $90M | $84M | $84M | $84M | $84M | $79M | $80M | $80M | $80M | $74M | $75M | $78M | |
| Financing Cash Flow | $-229M | $-152M | $-287M | $-247M | $-293M | $-561M | $-170M | $1.77B | $-363M | $-153M | $130M | $-83M | $189M | $-76M | $-545M | $-474M | |
| Net Change in Cash | $233M | $-27M | $-12M | $113M | $131M | $-361M | $-215M | $493M | $-203M | $-212M | $543M | $17M | $-49M | $-140M | $-385M | $-90M | |
| Free Cash Flow | · | $164M | · | · | · | $197M | · | · | · | $50M | · | · | · | $-33M | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | $13M | · | · | · | $-61M | · | · |
Rentabilidad 7
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 15.1% | 13.8% | · | 13.7% | 15.9% | 13.1% | · | 13.3% | 14.8% | 12.7% | · | 14.9% | 14.9% | 13.1% | · | 15.8% | |
| Net Margin | 10.5% | 8.7% | · | 8.7% | 10.2% | 8.3% | · | 9.1% | 9.6% | 8.2% | · | 9.8% | 10.1% | 8.7% | · | 10.3% | |
| Pretax Margin | 13.5% | 11.5% | · | 11.7% | 13.9% | 10.4% | · | 11.9% | 13.1% | 11.2% | · | 13.0% | 13.6% | 11.9% | · | 14.1% | |
| EBITDA Margin | 19.9% | 18.9% | · | 18.8% | 21.0% | 18.3% | · | 18.3% | 19.7% | 17.6% | · | 19.7% | 19.7% | 17.7% | · | 20.1% | |
| ROA | 1.9% | 1.6% | · | 1.5% | 1.9% | 1.5% | · | 1.5% | 1.7% | 1.5% | · | 1.7% | 1.8% | 1.5% | · | 1.9% | |
| ROE | 4.3% | 3.5% | · | 3.5% | 4.1% | 3.3% | · | 3.4% | 3.6% | 3.1% | · | 3.5% | 3.7% | 3.2% | · | 4.0% | |
| ROIC | 2.7% | 4.0% | · | 3.8% | 4.2% | 3.9% | · | 2.0% | 3.8% | 3.1% | · | 3.9% | 3.9% | 3.9% | · | 4.8% |
Liquidez y Solvencia 5
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.6 | 1.2 | · | 1.1 | 1.1 | 1.4 | · | 1.3 | 1.0 | 1.0 | · | 1.1 | 0.9 | 1.3 | · | 1.5 | |
| Quick Ratio | 1.3 | 0.9 | · | 0.9 | 0.9 | 1.1 | · | 1.0 | 0.8 | 0.8 | · | 0.9 | 0.7 | 1.1 | · | 1.2 | |
| Debt / Equity | 0.8 | 0.1 | · | 0.1 | 0.1 | 0.0 | · | 0.9 | 0.1 | 0.1 | · | 0.0 | 0.1 | 0.0 | · | 0.0 | |
| LT Debt / Equity | 0.7 | · | · | · | · | · | · | 0.8 | · | · | · | · | · | · | · | · | |
| Interest Coverage | · | · | · | · | · | · | · | · | 7.6 | 6.1 | · | 8.3 | 8.9 | 8.2 | · | 10.6 |
Eficiencia 3
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | |
| Inventory Turnover | 9.6 | 9.4 | · | 10.1 | 9.9 | 9.7 | · | 9.1 | 8.7 | 8.6 | · | 8.4 | 8.3 | 8.1 | · | 8.3 | |
| Receivables Turnover | 2.0 | 1.9 | · | 2.0 | 2.0 | 1.9 | · | 1.9 | 1.9 | 1.8 | · | 1.8 | 1.8 | 1.8 | · | 1.8 |
Valoración (TTM) 14
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $11.52B | $11.12B | · | $10.72B | $10.30B | $9.90B | · | $9.55B | $9.40B | $9.33B | · | $9.45B | $9.61B | $9.88B | · | $10.32B | |
| Net Income TTM | $1.10B | $999M | · | $973M | $957M | $869M | · | $874M | $883M | $856M | · | $918M | $927M | $1.05B | · | $1.35B | |
| Market Cap | $23.31B | $21.75B | · | $21.15B | $20.12B | $18.95B | · | $17.39B | $15.19B | $14.78B | · | $13.65B | $15.74B | $15.85B | · | $13.99B | |
| Enterprise Value | $28.33B | $21.86B | · | $21.23B | $20.30B | $18.76B | · | $22.88B | $15.53B | $15.21B | · | $13.81B | $16.13B | $15.67B | · | $13.29B | |
| P/E | 21.8 | 22.2 | · | 22.3 | 21.3 | 22.0 | · | 20.2 | 17.6 | 17.7 | · | 15.3 | 17.7 | 16.0 | · | 11.1 | |
| P/S | 2.0 | 2.0 | · | 2.0 | 2.0 | 1.9 | · | 1.8 | 1.6 | 1.6 | · | 1.4 | 1.6 | 1.6 | · | 1.4 | |
| P/B | 3.1 | 3.0 | · | 2.9 | 2.8 | 2.7 | · | 2.6 | 2.3 | 2.3 | · | 2.1 | 2.5 | 2.6 | · | 2.2 | |
| P / Cash Flow | · | 78.3 | · | · | · | 60.4 | · | · | · | 95.9 | · | · | · | 168.6 | · | · | |
| P / FCF | · | 132.6 | · | · | · | 96.2 | · | · | · | 295.5 | · | · | · | -480.2 | · | · | |
| EV / EBITDA | 46.8 | 40.0 | · | 40.2 | 34.9 | 38.6 | · | 50.3 | 32.9 | 36.6 | · | 30.5 | 35.1 | 38.0 | · | 26.6 | |
| EV / FCF | · | 133.3 | · | · | · | 95.2 | · | · | · | 304.1 | · | · | · | -474.9 | · | · | |
| EV / Revenue | 2.5 | 2.0 | · | 2.0 | 2.0 | 1.9 | · | 2.4 | 1.7 | 1.6 | · | 1.5 | 1.7 | 1.6 | · | 1.3 | |
| Earnings Yield | 4.6% | 4.5% | · | 4.5% | 4.7% | 4.5% | · | 5.0% | 5.7% | 5.6% | · | 6.5% | 5.7% | 6.2% | · | 9.0% | |
| Payout Ratio | · | 34.9% | · | · | · | 38.2% | · | · | · | 40.7% | · | · | · | 36.6% | · | · |
Estados Financieros Estado de resultados, balance general, flujo de caja — anual, últimos 5 años
Estado de resultados
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Ingresos | $11.04B | $9.87B | $9.25B | $9.88B | $10.79B |
| Margen Operativo % | 14.1% | 13.6% | 13.6% | 14.4% | 22.1% |
| Beneficio neto | $992M | $871M | $854M | $946M | $2.00B |
| EPS Diluido | $8.75 | $7.69 | $7.49 | $7.97 | $15.55 |
Balance general
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Deuda / Patrimonio | 0.8 | 0.9 | 0.7 | 0.7 | 0.6 |
| Ratio corriente | 1.0 | 1.1 | 1.3 | 1.2 | 1.6 |
| Ratio Rápido | 0.8 | 0.9 | 1.0 | 1.0 | 1.3 |
Flujo de Efectivo
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Flujo de caja libre | $1.36B | $909M | $864M | $1.31B | $1.83B |
Últimas noticias Noticias recientes que mencionan a esta empresa
Mis Métricas Tu lista de seguimiento personal — filas seleccionadas de Fundamentales Completos
📊
Elige las métricas que te importan — haz clic en el ➕ junto a cualquier fila en Fundamentales Completos arriba.
Tu selección se guarda y te sigue en todos los tickers.
Propietarios institucionales (13F) 1 175 declarantes · $12.9B total · A fecha de 30 de junio de 2026
Instituciones que informan tener esta acción en su Formulario 13F trimestral de la SEC. Solo posiciones largas; un solo presentador puede aparecer dos veces para tramos de opciones separados. Las patas de put/call de compensación grandes suelen reflejar la creación de mercado o el inventario cubierto, no la convicción direccional.
Actividad institucional — Q2 2026 vs trimestre anterior
| Nuevas posiciones | Posiciones cerradas | Aumentado | Disminuido | Cambio neto de acciones |
|---|---|---|---|---|
| 121 (-13 vs trimestre anterior) | 63 (-19 vs trimestre anterior) | 408 (+62 vs trimestre anterior) | 330 (-21 vs trimestre anterior) | +21.9M |
Comparado con Q1 2026. Las presentaciones del Formulario 13F de la SEC vencen dentro de los 45 días posteriores al final del trimestre, más un pequeño margen para los presentadores tardíos; los trimestres que aún se encuentran dentro de esa ventana se omiten en favor del par más reciente completamente reportado.
| Institución | Valor | Acciones | % de 13F rastreadas | Tipo |
|---|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $1 533 117 858 | 7 233 394 | 11,92% | Acciones |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $1 299 474 988 | 6 131 045 | 10,11% | Acciones |
| STATE STREET CORP | $1 169 252 484 | 5 516 643 | 9,09% | Acciones |
| GEODE CAPITAL MANAGEMENT, LLC | $584 135 885 | 2 767 754 | 4,54% | Acciones |
| EdgePoint Investment Group Inc. | $476 372 038 | 2 247 568 | 3,71% | Acciones |
| Grantham, Mayo, Van Otterloo & Co. LLC | $400 206 122 | 1 888 207 | 3,11% | Acciones |
| DIMENSIONAL FUND ADVISORS LP | $357 050 202 | 1 684 597 | 2,78% | Acciones |
| Davis Selected Advisers | $329 781 509 | 1 555 612 | 2,57% | Acciones |
| VICTORY CAPITAL MANAGEMENT INC | $311 037 928 | 1 467 506 | 2,42% | Acciones |
| NORGES BANK | $298 133 109 | 1 406 620 | 2,32% | Acciones |
| FMR LLC | $227 315 614 | 1 072 496 | 1,77% | Acciones |
| AMERICAN CENTURY COMPANIES INC | $173 422 135 | 818 220 | 1,35% | Acciones |
| M&G PLC | $168 677 800 | 795 650 | 1,31% | Acciones |
| VANGUARD FIDUCIARY TRUST CO | $131 756 386 | 621 639 | 1,02% | Acciones |
| ALLIANCEBERNSTEIN L.P. | $122 662 706 | 625 894 | 0,95% | Acciones |
| AMERIPRISE FINANCIAL INC | $109 652 758 | 517 352 | 0,85% | Acciones |
| Woodline Partners LP | $102 974 000 | 485 841 | 0,80% | Acciones |
| FIDUCIARY MANAGEMENT INC /WI/ | $102 489 906 | 483 557 | 0,80% | Acciones |
| Artemis Investment Management LLP | $99 175 856 | 467 921 | 0,77% | Acciones |
| CRAWFORD INVESTMENT COUNSEL INC | $97 514 204 | 460 081 | 0,76% | Acciones |
| PRINCIPAL FINANCIAL GROUP INC | $91 995 201 | 434 042 | 0,72% | Acciones |
| ENVESTNET ASSET MANAGEMENT INC | $90 834 224 | 428 564 | 0,71% | Acciones |
| SCHRODER INVESTMENT MANAGEMENT GROUP | $86 608 697 | 407 302 | 0,67% | Acciones |
| BNP PARIBAS FINANCIAL MARKETS | $83 772 178 | 395 245 | 0,65% | Acciones |
| M.D. Sass, LLC | $76 397 960 | 360 453 | 0,59% | Acciones |
| Qube Research & Technologies Ltd | $72 783 206 | 343 398 | 0,57% | Acciones |
| MACKENZIE FINANCIAL CORP | $70 641 875 | 333 295 | 0,55% | Acciones |
| Advisors Capital Management, LLC | $69 429 626 | 327 575 | 0,54% | Acciones |
| Swiss National Bank | $65 683 305 | 309 900 | 0,51% | Acciones |
| Balyasny Asset Management L.P. | $58 364 883 | 275 371 | 0,45% | Acciones |
| Mitsubishi UFJ Asset Management Co., Ltd. | $56 877 630 | 268 354 | 0,44% | Acciones |
| RHUMBLINE ADVISERS | $56 744 612 | 267 727 | 0,44% | Acciones |
| BlackRock, Inc. | $55 976 419 | 264 102 | 0,44% | Acciones |
| Sumitomo Mitsui Trust Group, Inc. | $54 809 634 | 258 597 | 0,43% | Acciones |
| VANGUARD ASSET MANAGEMENT, Ltd | $53 654 295 | 253 146 | 0,42% | Acciones |
| Quantinno Capital Management LP | $53 607 358 | 252 924 | 0,42% | Acciones |
| RAYMOND JAMES FINANCIAL INC | $53 249 860 | 251 238 | 0,41% | Acciones |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | $52 211 551 | 246 339 | 0,41% | Acciones |
| VAN LANSCHOT KEMPEN INVESTMENT MANAGEMENT N.V. | $51 484 139 | 242 907 | 0,40% | Acciones |
| Clark Capital Management Group, Inc. | $51 259 362 | 241 846 | 0,40% | Acciones |
| Vanguard Global Advisers, LLC | $51 025 267 | 240 742 | 0,40% | Acciones |
| Legal & General Group Plc | $50 185 731 | 236 781 | 0,39% | Acciones |
| FIL Ltd | $49 419 958 | 233 168 | 0,38% | Acciones |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $49 341 000 | 232 797 | 0,38% | Acciones |
| Eurizon Capital SGR S.p.A. | $47 173 414 | 222 564 | 0,37% | Acciones |
| BARCLAYS PLC | $45 003 978 | 212 333 | 0,35% | Acciones |
| PFA Pension, Forsikringsaktieselskab | $43 579 660 | 205 613 | 0,34% | Acciones |
| Integral Health Asset Management, LLC | $42 390 000 | 200 000 | 0,33% | Acciones |
| California Public Employees Retirement System | $41 574 204 | 196 151 | 0,32% | Acciones |
| CONNING INC. | $39 578 271 | 186 734 | 0,31% | Acciones |
| SEB Asset Management AB | $38 766 863 | 182 906 | 0,30% | Acciones |
| BANK OF MONTREAL /CAN/ | $38 512 587 | 181 706 | 0,30% | Acciones |
| GOLDMAN SACHS GROUP INC | $38 322 295 | 180 808 | 0,30% | Acciones |
| Boston Partners | $35 509 632 | 167 514 | 0,28% | Acciones |
| Focus Partners Wealth | $34 616 947 | 163 327 | 0,27% | Acciones |
| STOREBRAND ASSET MANAGEMENT AS | $34 117 592 | 160 970 | 0,27% | Acciones |
| COOKSON PEIRCE & CO INC | $32 977 089 | 155 589 | 0,26% | Acciones |
| UBS Group AG | $32 934 699 | 155 389 | 0,26% | Acciones |
| BRAUN STACEY ASSOCIATES INC | $32 724 232 | 154 396 | 0,25% | Acciones |
| Willis Investment Counsel | $32 110 425 | 151 500 | 0,25% | Acciones |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $31 795 403 | 162 238 | 0,25% | Acciones |
| LPL Financial LLC | $30 325 576 | 143 079 | 0,24% | Acciones |
| APG Asset Management N.V. | $27 869 580 | 150 334 | 0,22% | Acciones |
| SILVERCREST ASSET MANAGEMENT GROUP LLC | $26 893 912 | 126 888 | 0,21% | Acciones |
| &PARTNERS | $26 382 365 | 124 363 | 0,21% | Acciones |
| JANE STREET GROUP, LLC | $25 942 680 | 122 400 | 0,20% | Opción de compra |
| BANK OF AMERICA CORP /DE/ | $25 492 499 | 120 276 | 0,20% | Acciones |
| Candriam S.C.A. | $25 459 925 | 120 238 | 0,20% | Acciones |
| Squarepoint Ops LLC | $24 974 280 | 117 831 | 0,19% | Acciones |
| Gotham Asset Management, LLC | $24 911 119 | 117 533 | 0,19% | Acciones |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $24 607 896 | 116 373 | 0,19% | Acciones |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | $24 569 456 | 115 921 | 0,19% | Acciones |
| Robeco Institutional Asset Management B.V. | $23 854 123 | 112 546 | 0,19% | Acciones |
| AEGON ASSET MANAGEMENT UK Plc | $22 866 862 | 107 888 | 0,18% | Acciones |
| TOCQUEVILLE ASSET MANAGEMENT L.P. | $22 670 926 | 106 964 | 0,18% | Acciones |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $22 530 921 | 106 303 | 0,18% | Acciones |
| MERCER GLOBAL ADVISORS INC /ADV | $22 064 117 | 104 101 | 0,17% | Acciones |
| Moran Wealth Management, LLC | $22 053 609 | 104 051 | 0,17% | Acciones |
| ABN AMRO Bank N.V. | $21 523 733 | 101 667 | 0,17% | Acciones |
| VIRGINIA RETIREMENT SYSTEMS ET Al | $21 496 202 | 123 876 | 0,17% | Acciones |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $21 322 170 | 100 600 | 0,17% | Opción de compra |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $21 146 252 | 99 770 | 0,16% | Acciones |
| AVIVA PLC | $20 378 569 | 96 148 | 0,16% | Acciones |
| SCHWARTZ INVESTMENT COUNSEL INC | $20 326 005 | 95 900 | 0,16% | Acciones |
| Boston Common Asset Management, LLC | $20 282 767 | 95 696 | 0,16% | Acciones |
| CAPTRUST FINANCIAL ADVISORS | $20 146 790 | 95 054 | 0,16% | Acciones |
| Midwest Trust Co | $20 113 207 | 94 896 | 0,16% | Acciones |
| LAZARD ASSET MANAGEMENT LLC | $20 035 210 | 94 528 | 0,16% | Acciones |
| FJARDE AP-FONDEN /FOURTH SWEDISH NATIONAL PENSION FUND | $19 842 759 | 93 620 | 0,15% | Acciones |
| BLAIR WILLIAM & CO/IL | $19 773 115 | 93 291 | 0,15% | Acciones |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $19 613 005 | 92 536 | 0,15% | Acciones |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $19 160 280 | 90 400 | 0,15% | Opción de venta |
| CITADEL ADVISORS LLC | $18 821 160 | 88 800 | 0,15% | Opción de compra |
| WELLINGTON MANAGEMENT GROUP LLP | $17 507 282 | 82 601 | 0,14% | Acciones |
| Foundry Partners, LLC | $17 338 432 | 102 473 | 0,13% | Acciones |
| MARSHALL WACE, LLP | $17 187 874 | 81 094 | 0,13% | Acciones |
| Coho Partners, Ltd. | $16 981 317 | 89 103 | 0,13% | Acciones |
| Copeland Capital Management, LLC | $16 902 800 | 79 749 | 0,13% | Acciones |
| CIBC Asset Management Inc | $16 674 318 | 78 671 | 0,13% | Acciones |
| Mitsubishi UFJ Trust & Banking Corp | $16 558 594 | 78 125 | 0,13% | Acciones |
Informantes de la empresa 53 insiders · 26 directivos · 26 consejeros
| Insider | Rol | Última actividad | Acciones en propiedad | Compras 12m | Ventas 12m | Neto 12m |
|---|---|---|---|---|---|---|
| E. J. Davis | CEO and President | 1 de junio de 2026 S | 132 423 | 0 | 5 | $-14 656 302 |
| Surya N Mohapatra | Chairman, President & CEO | 30 de abril de 2012 F | 243 713 | 0 | 0 | $0 |
| Sam Samad | Executive Vice President & CFO | 22 de julio de 2026 A | 33 478 | 0 | 0 | $0 |
| Mark Guinan | Executive Vice President & CFO | 7 de marzo de 2022 F | 98 981 | 0 | 0 | $0 |
| Robert Hagemann | SVP & Chief Financial Officer | 5 de marzo de 2013 F | 126 722 | 0 | 0 | $0 |
| Mark E Delaney | SVP & Chief Commercial Officer | 28 de julio de 2026 S | 10 335 | 0 | 1 | $-376 288 |
| Karthik Kuppusamy | SVP, Clinical Solutions | 22 de julio de 2026 L | 13 557 | 0 | 2 | $-2 167 772 |
| Patrick Plewman | SVP for Diagnostic Services | 22 de julio de 2026 L | 15 293 | 0 | 5 | $-3 023 678 |
| Catherine T. Doherty | EVP, Regional Businesses | 5 de marzo de 2026 S | 67 122 | 0 | 7 | $-6 671 228 |
| Michael E Prevoznik | SVP & General Counsel | 5 de marzo de 2026 S | 37 557 | 0 | 7 | $-6 505 199 |
| Michael J Deppe | SVP, Corp. Controller & CAO | 4 de marzo de 2026 F | 35 196 | 0 | 0 | $0 |
| Mark A Gardner | SVP of Molecular Gen & Oncol | 24 de septiembre de 2024 F | 4 673 | 0 | 0 | $0 |
| Manner Carrie Eglinton | SVP, Advanced Diagnostics | 7 de marzo de 2022 F | 48 391 | 0 | 0 | $0 |
| Manuel O. Mendez | SVP & Chief Commercial Officer | 17 de febrero de 2021 A | 29 045 | 0 | 0 | $0 |
| Robert A Klug | VP, Corporate Controller | 1 de marzo de 2019 F | 6 261 | 0 | 0 | $0 |
| Jon R Cohen | SVP & Group Exec. Diag. Sol. | 8 de marzo de 2018 M | 31 757 | 0 | 0 | $0 |
| Everett Cunningham | SVP, Commercial | 1 de marzo de 2018 G | 37 760 | 0 | 0 | $0 |
| Thomas F Bongiorno | VP and Corporate Controller | 2 de marzo de 2015 F | 11 837 | 0 | 0 | $0 |
| John B. Haydon | SVP, Operations | 13 de febrero de 2014 A | 19 890 | 0 | 0 | $0 |
| Kathy Ordonez | SVP, Diagnostic Solutions | 31 de marzo de 2013 F | 9 569 | 0 | 0 | $0 |
| Joan Elizabeth Miller | SVP-Oncology & Neurology Srvcs | 29 de febrero de 2012 F | 89 232 | 0 | 0 | $0 |
| Wayne R. Simmons | Vice President, Operations | 16 de junio de 2011 M | 47 150 | 0 | 0 | $0 |
| Robert E Peters | VP, Sales & Marketing | 12 de febrero de 2007 A | 12 974 | 0 | 0 | $0 |
| David M Zewe | SVP, Diagnostic Testing Ops | 12 de febrero de 2007 A | 31 079 | 0 | 0 | $0 |
| GRANT THOMAS W II | Sr VP, Ins. & Employer Serv. | 12 de febrero de 2007 A | — | 0 | 0 | $0 |
| Gerald C Marrone | SVP, Administration | 28 de febrero de 2004 F | 49 609 | 0 | 0 | $0 |
| Wright Lassiter III | Consejero | 22 de julio de 2026 L | 10 323 | 0 | 0 | $0 |
| Vicky B Gregg | Consejero | 22 de julio de 2026 A | 18 386 | 0 | 1 | $-239 700 |
| Robert B Carter | Consejero | 22 de julio de 2026 L | 3 864 | 0 | 0 | $0 |
| Timothy L Main | Consejero | 22 de julio de 2026 L | 22 460 | 0 | 0 | $0 |
| Timothy C Wentworth | Consejero | 1 de julio de 2026 A | 1 358 | 0 | 0 | $0 |
| Timothy M Ring | Consejero | 20 de mayo de 2026 A | 31 140 | 0 | 0 | $0 |
| Gary M Pfeiffer | Consejero | 20 de mayo de 2026 A | 31 005 | 0 | 1 | $-270 317 |
| Luis Diaz | Consejero | 15 de mayo de 2025 A | 4 054 | 0 | 0 | $0 |
| Tracey Doi | Consejero | 15 de mayo de 2025 A | 6 490 | 0 | 0 | $0 |
| Gail R Wilensky | Consejero | 17 de mayo de 2023 A | 20 506 | 0 | 0 | $0 |
| Stephen H Rusckowski | Consejero | 6 de marzo de 2023 F | 389 597 | 0 | 0 | $0 |
| Helen Torley | Consejero | 25 de mayo de 2021 A | 6 260 | 0 | 0 | $0 |
| Daniel Stanzione | Consejero | 23 de noviembre de 2020 S | 28 349 | 0 | 0 | $0 |
| Jenne K Britell | Consejero | 4 de junio de 2018 G | 14 479 | 0 | 0 | $0 |
| Jeffrey M Leiden | Consejero | 29 de mayo de 2018 S | 6 000 | 0 | 0 | $0 |
| John B Ziegler | Consejero | 22 de febrero de 2017 S | 16 557 | 0 | 0 | $0 |
| John C Baldwin MD | Consejero | 12 de agosto de 2015 S | 12 949 | 0 | 0 | $0 |
| William F Buehler | Consejero | 12 de febrero de 2014 M | 26 225 | 0 | 0 | $0 |
| GSK plc | Consejero | 31 de enero de 2011 S | 0 | 0 | 0 | $0 |
| Rosanne Haggerty | Consejero | 6 de mayo de 2010 A | 9 334 | 0 | 0 | $0 |
| William R Grant | Consejero | 1 de abril de 2007 A | 3 334 | 0 | 0 | $0 |
| James F Flaherty III | Consejero | 4 de mayo de 2006 A | 1 667 | 0 | 0 | $0 |
| Kenneth D Brody | Consejero | 28 de abril de 2004 S | 0 | 0 | 0 | $0 |
| Mary A Cirillo | Consejero | 1 de abril de 2004 A | 2 627 | 0 | 0 | $0 |
Informantes de las presentaciones SEC Form 3/4/5; neto = solo P/S de mercado abierto
Activistas y propietarios del %+ 5 13 tenencias
Inversores que presentaron el Anexo 13D de la SEC — propiedad beneficiosa superior al % 5 con la intención de influir en el emisor (participaciones activistas, campañas de la junta directiva, M&A). Cada fila muestra el estado conocido más reciente de la posición de ese declarante.
| Declarante | Presentado | Participación | Estado | Propósito | Presentación |
|---|---|---|---|---|---|
| Quest Diagnostics Incorporated | 18 de mayo de 2011 | — | Presentación inicial | M&A / venta | SEC |
| Persona informante no revelada | 1 de febrero de 2011 | — | Presentación inicial | Inversión pasiva | SEC |
| Persona informante no revelada | 20 de marzo de 2009 | — | Presentación inicial | — | SEC |
| GlaxoSmithKline plc ×2 presentaciones | 18 de septiembre de 2008 | — | Presentación inicial | — | SEC |
| Persona informante no revelada | 16 de febrero de 2007 | — | Presentación inicial | — | SEC |
| Quest Diagnostics Incorporated - (FEIN No. ×2 presentaciones | 19 de enero de 2006 | — | Presentación inicial | — | SEC |
| Persona informante no revelada | 15 de diciembre de 2004 | — | Presentación inicial | — | SEC |
| Persona informante no revelada | 29 de junio de 2004 | — | Presentación inicial | — | SEC |
| Persona informante no revelada | 24 de junio de 2002 | — | Presentación inicial | M&A / venta | SEC |
| Persona informante no revelada | 22 de mayo de 2002 | — | Presentación inicial | — | SEC |
| Persona informante no revelada | 12 de abril de 2002 | — | Presentación inicial | M&A / venta | SEC |
| IRS Identification Nos. of Above Persons (entities only) Quest Diagnostics Ventures LLC - (FEIN No., Quest Diagnostics Incorporated - (FEIN No. ×3 presentaciones | 1 de noviembre de 2001 | — | Presentación inicial | M&A / venta | SEC |
| Persona informante no revelada | 14 de mayo de 2001 | — | Presentación inicial | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Propiedad de ETFs Mantenido por 183 ETFs
El peso refleja solo las tenencias directas de acciones (N-PORT); los fondos apalancados o basados en derivados pueden tener exposición adicional a swaps no mostrada.
| Fondo | Ponderación | Unidades | A fecha de | Fuente |
|---|---|---|---|---|
| IHF · iShares Trust | 3,91% | 203 179 SH | 8 de agosto de 2026 | Diario |
| RSPH · Invesco Exchange-Traded Fund Trust | 1,77% | 58 107 SH | 8 de agosto de 2026 | Diario |
| FXH · First Trust Exchange-Traded AlphaDE… | 1,29% | 57 932 NS | 30 de abril de 2026 | N-PORT |
| CZA · Invesco Exchange-Traded Fund Trust | 1,22% | 9 813 SH | 8 de agosto de 2026 | Diario |
| TMFX · RBB Fund, Inc. | 1,05% | 1 724 NS | 31 de mayo de 2026 | N-PORT |
| ANEW · ProShares Trust | 0,92% | 364 NS | 31 de mayo de 2026 | N-PORT |
| QLTY · GMO ETF Trust | 0,85% | 196 208 NS | 31 de mayo de 2026 | N-PORT |
| ALTL · Pacer Funds Trust | 0,82% | 4 047 NS | 30 de abril de 2026 | N-PORT |
| LSEQ · Harbor ETF Trust | 0,80% | 635 NS | 30 de abril de 2026 | N-PORT |
| SPVM · Invesco Exchange-Traded Fund Trust | 0,76% | 4 201 SH | 8 de agosto de 2026 | Diario |
| QLV · FlexShares Trust | 0,74% | 6 461 NS | 30 de abril de 2026 | N-PORT |
| GDOC · Goldman Sachs ETF Trust | 0,72% | 741 NS | 31 de mayo de 2026 | N-PORT |
| ESMV · iShares Trust | 0,72% | 236 SH | 8 de agosto de 2026 | Diario |
| HUSV · First Trust Exchange-Traded Fund III | 0,52% | 1 956 NS | 30 de abril de 2026 | N-PORT |
| ITAN · EA Series Trust | 0,46% | 2 110 NS | 29 de mayo de 2026 | N-PORT |
| QQWZ · Pacer Funds Trust | 0,44% | 1 055 NS | 30 de abril de 2026 | N-PORT |
| COWZ · Pacer Funds Trust | 0,44% | 409 814 NS | 30 de abril de 2026 | N-PORT |
| IYH · iShares Trust | 0,43% | 66 179 SH | 8 de agosto de 2026 | Diario |
| SIXL · EXCHANGE TRADED CONCEPTS TRUST | 0,41% | 3 999 NS | 31 de mayo de 2026 | N-PORT |
| VOE · VANGUARD INDEX FUNDS | 0,40% | 711 079 SH | 8 de agosto de 2026 | Diario |
| JPUS · J.P. Morgan Exchange-Traded Fund Tr… | 0,38% | 8 682 NS | 30 de abril de 2026 | N-PORT |
| JPME · J.P. Morgan Exchange-Traded Fund Tr… | 0,37% | 8 368 NS | 30 de abril de 2026 | N-PORT |
| IMCV · iShares Trust | 0,37% | 17 734 SH | 8 de agosto de 2026 | Diario |
| FHLC · FIDELITY COVINGTON TRUST | 0,35% | 51 278 NS | 30 de abril de 2026 | N-PORT |
| SUSA · iShares Trust | 0,35% | 60 308 SH | 8 de agosto de 2026 | Diario |
| FTA · First Trust Exchange-Traded AlphaDE… | 0,34% | 23 030 NS | 30 de abril de 2026 | N-PORT |
| VHT · VANGUARD WORLD FUND | 0,34% | 330 273 SH | 8 de agosto de 2026 | Diario |
| IXJ · iShares Trust | 0,33% | 58 047 SH | 8 de agosto de 2026 | Diario |
| RXL · ProShares Trust | 0,31% | 1 147 NS | 31 de mayo de 2026 | N-PORT |
| CURE · Direxion Shares ETF Trust | 0,31% | 2 194 NS | 30 de abril de 2026 | N-PORT |
| GNOM · Global X Funds | 0,28% | 789 NS | 31 de mayo de 2026 | N-PORT |
| DFLV · Dimensional ETF Trust | 0,26% | 79 983 NS | 30 de abril de 2026 | N-PORT |
| BSCT · Invesco Exchange-Traded Self-Indexe… | 0,26% | 7 703 000 | 8 de agosto de 2026 | Diario |
| IWS · iShares Trust | 0,25% | 166 611 SH | 8 de agosto de 2026 | Diario |
| FEX · First Trust Exchange-Traded AlphaDE… | 0,24% | 18 806 NS | 30 de abril de 2026 | N-PORT |
| JVAL · J.P. Morgan Exchange-Traded Fund Tr… | 0,24% | 8 995 NS | 30 de abril de 2026 | N-PORT |
| EQIN · Columbia ETF Trust I | 0,23% | 3 340 NS | 30 de abril de 2026 | N-PORT |
| JMOM · J.P. Morgan Exchange-Traded Fund Tr… | 0,23% | 26 229 NS | 30 de abril de 2026 | N-PORT |
| SIZE · iShares Trust | 0,23% | 4 242 SH | 8 de agosto de 2026 | Diario |
| VO · VANGUARD INDEX FUNDS | 0,23% | 2 398 948 SH | 8 de agosto de 2026 | Diario |
| BFOR · ALPS ETF Trust | 0,22% | 2 467 NS | 31 de mayo de 2026 | N-PORT |
| EUSA · iShares, Inc. | 0,22% | 17 880 SH | 8 de agosto de 2026 | Diario |
| DFVE · DoubleLine ETF Trust | 0,22% | 307 NS | 31 de marzo de 2026 | N-PORT |
| VFMV · VANGUARD WELLINGTON FUND | 0,22% | 4 307 SH | 8 de agosto de 2026 | Diario |
| RSP · Invesco Exchange-Traded Fund Trust | 0,22% | 910 753 SH | 8 de agosto de 2026 | Diario |
| GSEW · Goldman Sachs ETF Trust | 0,20% | 18 310 NS | 31 de mayo de 2026 | N-PORT |
| ACWV · iShares, Inc. | 0,20% | 28 277 SH | 8 de agosto de 2026 | Diario |
| DEUS · DBX ETF Trust | 0,20% | 2 734 NS | 29 de mayo de 2026 | N-PORT |
| IWR · iShares Trust | 0,19% | 449 590 SH | 8 de agosto de 2026 | Diario |
| IMCB · iShares Trust | 0,18% | 12 737 SH | 8 de agosto de 2026 | Diario |